HeartSciences Inc.
Close on Oct 19, 2026
- Market cap
- $11.26M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Dec 14, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jul 31, 2026 | Sep 15, 2026 | After market close | – | – | – |
| Q4 FY2026 Ended Apr 30, 2026 | Jul 29, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Jan 31, 2026 | Mar 16, 2026 | After market close | – | – | – |
| Q2 FY2026 Ended Oct 31, 2025 | Dec 15, 2025 | After market close | – | – | – |
| Q1 FY2026 Ended Jul 31, 2025 | Sep 11, 2025 | After market close | – | – | – |
| Q4 FY2025 Ended Apr 30, 2025 | Jul 24, 2025 | After market close | – | – | – |
| Q3 FY2025 Ended Jan 31, 2025 | Mar 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Oct 31, 2024 | Dec 16, 2024 | After market close | – | – | – |
| Q1 FY2025 Ended Jul 31, 2024 | Sep 12, 2024 | After market close | – | – | – |
| Q4 FY2024 Ended Apr 30, 2024 | Jul 29, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Jan 31, 2024 | Mar 14, 2024 | After market close | – | – | – |
Press releases
Announcements HeartSciences filed with the SEC
PRESS RELEASE, DATED OCTOBER 6, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 17, 2026.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED SEPTEMBER 15, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 20, 2026.
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 19, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 29, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 23, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
CONFERENCE CALL TRANSCRIPT, DATED JUNE 23, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
SOCIAL MEDIA POSTS, DATED JUNE 23, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED JUNE 23, 2026
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STRICTLY PRIVATE AND CONFIDENTIAL J U N E 2 0 2 6 PROJECT CORDIS INVESTOR PRESENTATION
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
CERTAIN FINANCIAL INFORMATION OF FORTITUDE
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Other events · EX-99.1 to Form 8-K
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value.
Other events · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Listing notice · Other events · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 29, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 4, 2024.
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED MARCH 14, 2024
Results of operations · EX-99.1 to Form 8-K
HEART TEST LABORATORIES, INC. D/B/A HEARTSCIENCES
Other events · EX-99.1 to Form 8-K
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
Other events · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results
Results of operations · Executive or director change · EX-99 to Form 8-K
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
Other events · EX-99.1 to Form 8-K
HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
Regulation FD disclosure · EX-99.1 to Form 8-K
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
Other events · EX-99.1 to Form 8-K
HeartSciences Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
HeartSciences Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K